The Norwegian is responsible for the aquafeed segment in Cargill and completing the merger of the two companies – a process which began in August.
“Functional feeds targeting fish health have dominated our research in recent years. That's where we have invested, and that is where we are now investing,” he told kyst.no.
Wathne believes Cargill’s investment in Chile, which is currently under construction, can take the company’s research capacity to a new level.
“We’ll be able to control test groups in infection experiments, we can dispense different feeds before introducing an infection or we can have fish that are sick and try new feeds on them afterwards,” he adds.
He is convinced that such a model is the future of feed development.
“We have a large library of components that we think will work, but we have to get it documented and the fish in facility can provide the answers to everything we want to know about feed,” he concludes.
“The increased investment in research is important for Cargill and EWOS, but the centre will also benefit the entire industry as a whole,” Wathne asserts.